Dr. Wei Ding’s the head of Bioinformatics and Data Science, Alexion AstraZeneca. With more than two decades of experience in the healthcare industry and academia, he has been leading data science and translational medicine efforts for advancing drug development and clinical research.
 
Before joining AstraZeneca, Dr. Ding held significant positions in various organizations. He served as the VP of Data Science at Dotlab, held roles as the CSO and Head of Research/Bioinformatics at Admera Health, acted as the Clinical Genomics Lead at Mount Sinai, and held the position of Principal Scientist at Schering Plough/Merck. In addition, he also served as an adjunct professor at Kean University. Dr. Ding has published over 40 peer reviewed papers and patents.
 
Dr. Ding obtained his Ph.D. in Biophysics from the State University of New York at Stony Brook, and B.S from the University of Science and Technology of China.

Dr. Wu is the Senior Director of Search & Evaluation at Takeda Oncology, where he is responsible for driving the assessment of late-stage business development opportunities in alignment with Takeda Oncology’s BD strategy and integrated Disease Area Strategies. He also collaborates on the development and execution of Takeda’s global oncology business development strategy.

​

Previously, he led Global Business Development at Antengene, securing over 15 strategic partnerships with companies such as Merck and Bristol Myers Squibb. Before that, he served as the U.S. Head of Business Development at Adlai Nortye USA Inc., managing collaborations with Novartis, Merck, and Eisai. His additional experience includes business development executive roles at ATCC and GenScript.

​

Dr. Wu holds an MBA from Columbia University and a PhD from North Carolina State University.